The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Estrogen plus Progestin and Colorectal Cancer in Postmenopausal Women
Abstract
BACKGROUND: Although the Women's Health Initiative (WHI) trial of estrogen plus progestin in postmenopausal women identified more overall health risks than benefits among women in the hormone group, the use of estrogen plus progestin was associated with a significant decrease in the risk of colorectal cancer. We analyzed features of the colorectal cancers that developed and their relation to the characteristics of the participants. METHODS: In the WHI trial, 16,608 postmenopausal women who were 50 to 79 years of age and had an intact uterus were randomly assigned to a combination of conjugated equine estrogens (0.625 mg per day) plus medroxyprogesterone acetate (2.5 mg per day) or placebo. The main outcome measures were the incidence, stages, and types of colorectal cancer, as determined by blinded central adjudication. RESULTS: There were 43 invasive colorectal cancers in the hormone group and 72 in the placebo group (hazard ratio, 0.56; 95 percent confidence interval, 0.38 to 0.81; P=0.003). The invasive colorectal cancers in the hormone group were similar in histologic features and grade to those in the placebo group but with a greater number of positive lymph nodes (mean +/-SD, 3.2+/-4.1 vs. 0.8+/-1.7; P=0.002) and were more advanced (regional or metastatic disease, 76.2 percent vs. 48.5 percent; P=0.004). In exploratory analyses, women in the hormone group with antecedent vaginal bleeding had colorectal cancers with a greater number of positive nodes than women in the hormone group who did not have vaginal bleeding (3.8+/-4.3 vs. 0.7+/-1.5 nodes, P=0.006). CONCLUSIONS: Relatively short-term use of estrogen plus progestin was associated with a decreased risk of colorectal cancer. However, colorectal cancers in women who took estrogen plus progestin were diagnosed at a more advanced stage than those in women who took placebo.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Writing Group for the Women's Health Initiative Investigators (2002) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.288.3.321 · Cited by 15,889
Jemal, A., Murray, T., Samuels, A., Ghafoor, A., Ward, E., & Thun, M. J. (2003) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.53.1.5 · Cited by 3,275
Design of the Women’s Health Initiative Clinical Trial and Observational Study
(1998) · Controlled Clinical Trials · doi:10.1016/s0197-2456(97)00078-0 · Cited by 2,585
Fundamentals of Clinical Chemistry.
(1977) · Annals of Internal Medicine · doi:10.7326/0003-4819-87-1-142_1 · Cited by 2,561
The Effect of Celecoxib, a Cyclooxygenase-2 Inhibitor, in Familial Adenomatous Polyposis
Steinbach, G., Lynch, P. M., Phillips, R. K. S., Wallace, M. H., Hawk, E., Gordon, G. B., Wakabayashi, N., Saunders, B., Shen, Y., Fujimura, T., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200006293422603 · Cited by 2,526
Shumaker, S. A., Legault, C., Rapp, S. R., Thal, L., Wallace, R. B., Ockene, J. K., Hendrix, S. L., Jones III, B. N., Assaf, A. R., Jackson, R. D., et al. (2003) · JAMA · doi:10.1001/jama.289.20.2651 · Cited by 2,178
Self-citationWINAWER, S. (2003) · Gastroenterology · doi:10.1053/gast.2003.50044 · Cited by 2,143
Grady, D., Herrington, D., Bittner, V., Blumenthal, R., Davidson, M., Hlatky, M., Hsia, J., Hulley, S., Herd, A., Khan, S., et al. (2002) · JAMA · doi:10.1001/jama.288.1.49 · Cited by 1,930
Chlebowski, R. T., Hendrix, S. L., Langer, R. D., Stefanick, M. L., Gass, M., Lane, D., Rodabough, R. J., Gilligan, M. A., Cyr, M. G., Thomson, C. A., et al. (2003) · JAMA · doi:10.1001/jama.289.24.3243 · Cited by 1,872
Self-citationTreatment of Colonic and Rectal Adenomas with Sulindac in Familial Adenomatous Polyposis
Giardiello, F. M., Hamilton, S. R., Krush, A. J., Piantadosi, S., Hylind, L. M., Celano, P., Booker, S. V., Robinson, C. R., & Offerhaus, G. J. A. (1993) · New England Journal of Medicine · doi:10.1056/nejm199305063281805 · Cited by 1,717
Cited by
Manson, J. E., Chlebowski, R. T., Stefanick, M. L., Aragaki, A. K., Rossouw, J. E., Prentice, R. L., Anderson, G., Howard, B. V., Thomson, C. A., LaCroix, A. Z., et al. (2013) · JAMA · doi:10.1001/jama.2013.278040 · Cited by 1,650
Self-citationBreast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Obesity and cancer risk: Emerging biological mechanisms and perspectives
Avgerinos, K. I., Spyrou, N., Mantzoros, C. S., & Dalamaga, M. (2019) · Metabolism · doi:10.1016/j.metabol.2018.11.001 · Cited by 1,567
Jemal, A., Clegg, L. X., Ward, E., Ries, L. A. G., Wu, X., Jamison, P. M., Wingo, P. A., Howe, H. L., Anderson, R. N., & Edwards, B. K. (2004) · Cancer · doi:10.1002/cncr.20288 · Cited by 1,140
The 2022 hormone therapy position statement of The North American Menopause Society
(2022) · Menopause · doi:10.1097/gme.0000000000002028 · Cited by 977
Treatment of symptoms of the menopause: an Endocrine Society Clinical Practice Guideline
Stuenkel, C. A., Davis, S. R., Gompel, A., Lumsden, M. A., Murad, M. H., Pinkerton, J. V., & Santen, R. J. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2236 · Cited by 884
Adiposity and cancer at major anatomical sites: umbrella review of the literature
Kyrgiou, M., Kalliala, I., Markozannes, G., Gunter, M. J., Paraskevaidis, E., Gabra, H., Martin-Hirsch, P., & Tsilidis, K. K. (2017) · BMJ · doi:10.1136/bmj.j477 · Cited by 803
Postmenopausal Hormone Therapy: An Endocrine Society Scientific Statement
Santen, R. J., Allred, D. C., Ardoin, S. P., Archer, D. F., Boyd, N., Braunstein, G. D., Burger, H. G., Colditz, G. A., Davis, S. R., Gambacciani, M., et al. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-2509 · Cited by 680
Adiposity and cancer risk: new mechanistic insights from epidemiology
Renehan, A. G., Zwahlen, M., & Egger, M. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3967 · Cited by 654
Obesity and colon and rectal cancer risk: a meta-analysis of prospective studies
Larsson, S. C., & Wolk, A. (2007) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/86.3.556 · Cited by 632
Long term hormone therapy for perimenopausal and postmenopausal women
Farquhar, C., Marjoribanks, J., Lethaby, A., Suckling, J. A., & Lamberts, Q. (2005) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004143.pub2 · Cited by 582
Pischon, T., Lahmann, P. H., Boeing, H., Friedenreich, C., Norat, T., Tjønneland, A., Halkjaer, J., Overvad, K., Clavel-Chapelon, F., Boutron-Ruault, M.-C., et al. (2006) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djj246 · Cited by 554
Long-term Use of Aspirin and Nonsteroidal Anti-inflammatory Drugs and Risk of Colorectal Cancer
Chan, A. T. (2005) · JAMA · doi:10.1001/jama.294.8.914 · Cited by 478
The Effects of Tibolone in Older Postmenopausal Women
Cummings, S. R., Ettinger, B., Delmas, P. D., Kenemans, P., Stathopoulos, V., Verweij, P., Mol-Arts, M., Kloosterboer, L., Mosca, L., Christiansen, C., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0800743 · Cited by 457
Long-term hormone therapy for perimenopausal and postmenopausal women
Marjoribanks, J., Farquhar, C., Roberts, H., Lethaby, A., & Lee, J. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004143.pub5 · Cited by 424
Labianca, R., Beretta, G. D., Kildani, B., Milesi, L., Merlin, F., Mosconi, S., Pessi, M. A., Prochilo, T., Quadri, A., Gatta, G., et al. (2010) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2010.01.010 · Cited by 409
Health Risks and Benefits 3 Years After Stopping Randomized Treatment With Estrogen and Progestin
Heiss, G. (2008) · JAMA · doi:10.1001/jama.299.9.1036 · Cited by 396
Keum, N., Greenwood, D. C., Lee, D. H., Kim, R., Aune, D., Ju, W., Hu, F. B., & Giovannucci, E. L. (2015) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv088 · Cited by 395
Labianca, R., Nordlinger, B., Beretta, G. D., Brouquet, A., & Cervantes, A. (2010) · Annals of Oncology · doi:10.1093/annonc/mdq168 · Cited by 340
Chlebowski, R. T., Schwartz, A. G., Wakelee, H., Anderson, G. L., Stefanick, M. L., Manson, J. E., Rodabough, R. J., Chien, J. W., Wactawski-Wende, J., Gass, M., et al. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61526-9 · Cited by 322
Self-citationMouse Model of Colonic Adenoma-Carcinoma Progression Based on Somatic Apc Inactivation
Hinoi, T., Akyol, A., Theisen, B. K., Ferguson, D. O., Greenson, J. K., Williams, B. O., Cho, K. R., & Fearon, E. R. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-2735 · Cited by 314
Long term hormone therapy for perimenopausal and postmenopausal women
Marjoribanks, J., Farquhar, C., Roberts, H., & Lethaby, A. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004143.pub4 · Cited by 278
Screening for Colorectal Cancer
Lieberman, D. A. (2009) · New England Journal of Medicine · doi:10.1056/nejmcp0902176 · Cited by 269
Bae, S., Ulrich, C. M., Neuhouser, M. L., Malysheva, O., Bailey, L. B., Xiao, L., Brown, E. C., Cushing-Haugen, K. L., Zheng, Y., Cheng, T.-Y. D., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1835 · Cited by 253
Extra-gonadal sites of estrogen biosynthesis and function
Barakat, R., Oakley, O., Kim, H., Jin, J., & Ko, C. J. (2016) · BMB Reports · doi:10.5483/bmbrep.2016.49.9.141 · Cited by 215
Risks and benefits of dietary isoflavones for cancer
Andres, S., Abraham, K., Appel, K. E., & Lampen, A. (2011) · Critical Reviews in Toxicology · doi:10.3109/10408444.2010.541900 · Cited by 168
Fedirko, V., Bostick, R. M., Long, Q., Flanders, W. D., McCullough, M. L., Sidelnikov, E., Daniel, C. R., Rutherford, R. E., & Shaukat, A. (2010) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-09-0448 · Cited by 150
Specialty supplements and breast cancer risk in the VITamins And Lifestyle (VITAL) Cohort
Brasky, T. M., Lampe, J. W., Potter, J. D., Patterson, R. E., & White, E. (2010) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-10-0318 · Cited by 109
Self-citationCoffee Consumption and Risk of Colorectal Cancer: A Meta-Analysis of Case-Control Studies
Galeone, C., Turati, F., La Vecchia, C., & Tavani, A. (2010) · Cancer Causes & Control · doi:10.1007/s10552-010-9623-5 · Cited by 86
Gilligan, L. C., Gondal, A., Tang, V., Hussain, M. T., Arvaniti, A., Hewitt, A.-M., & Foster, P. A. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00103 · Cited by 32
Adenoma detection rate in 41,010 patients from Southwest China
CAI, B., LIU, Z., XU, Y., WEI, W., & ZHANG, S. (2015) · Oncology Letters · doi:10.3892/ol.2015.3005 · Cited by 22
Metadata
- Authors
- Chlebowski, R. T., Wactawski-Wende, J., Ritenbaugh, C., Hubbell, F. A., Ascensao, J., Rodabough, R. J., Rosenberg, C. A., Taylor, V. M., Harris, R., Chen, C., Adams-Campbell, L. L., & White, E.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2004-03-04
- Volume
- 350
- Issue
- 10
- Pages
- 991-1004
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2164414963
- Cited by
- 669
- References
- 39
- FWCI
- 25.38
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.